STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Karo Bio AB (publ)(STO:KARO) is organizing a symposium in Stockholm on May 16-17, where key researchers from the industry and the academic community present and discuss the frontier of research in the field of estrogen receptor beta (ER-beta) and its therapeutic applications. At the symposium, promising results for ER-beta selective compounds in preclinical models of multiple sclerosis (MS) will be described. MS is a prioritized indication and represents a great commercial opportunity for Karo Bio’s ER-beta program.
